- Home
- RNXT
RNXT
RenovoRx Inc.
as 11-14-2024 12:37pm EST
RenovoRx Inc is a clinical-stage biopharmaceutical company developing proprietary targeted combination therapies for high unmet medical need with a goal to improve therapeutic outcomes for cancer patients undergoing treatment. RenovoRx's patented Trans-Arterial Micro-Perfusion therapy platform is designed to ensure precise therapeutic delivery to directly target the tumor while potentially minimizing a therapy's toxicities versus systemic intravenous therapy.
| Founded: | 2012 | Country: | United States |
| Employees: | N/A | City: | SAN JOSE |
| Market Cap: | 21.6M | IPO Year: | 2021 |
| Target Price: | $6.13 | AVG Volume (30 days): | 29.1K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 3 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -0.54 | EPS Growth: | N/A |
| 52 Week Low/High: | $0.53 - $2.35 | Next Earning Date: | 11-13-2024 |
| Revenue: | N/A | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
Latest RenovoRx Inc. News
RNXT Breaking Stock News: Dive into RNXT Ticker-Specific Updates for Smart Investing
GlobeNewswire
14 hours ago
RenovoRx Reports Third Quarter 2024 Financial Results and Operational Highlights
Simply Wall St.
2 months ago
We Think RenovoRx (NASDAQ:RNXT) Needs To Drive Business Growth Carefully
GlobeNewswire
2 months ago
RenovoRx Increases Production of FDA-Cleared RenovoCath® Delivery System in Response to Strong Demand from Oncology and Interventional Radiology Physicians
GlobeNewswire
2 months ago
RenovoRx Announces Presentation at Symposium on Clinical Interventional Oncology Highlighting TAMP™ for Targeted Treatment of Locally Advanced Pancreatic Cancer
GlobeNewswire
3 months ago
RenovoRx CEO Shaun Bagai to Present at H.C. Wainwright’s 26th Annual Global Investment Conference on September 9, 2024 in New York
Medical Device Network
3 months ago
RenovoRx continues drug-device combo Phase III trial in pancreatic cancer
GlobeNewswire
3 months ago
RenovoRx Announces First Patient Enrolled at University of Nebraska Medical Center for the Ongoing Pivotal Phase III TIGeR-PaC Clinical Trial
GlobeNewswire
3 months ago
RenovoRx Announces Publication of Positive Early-Stage Clinical Data in International Peer-Reviewed Journal, The Oncologist®
Compare RNXT vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "RNXT RenovoRx Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.